Erudio Healtherudio.com
Sponsor
Roche trials: what clinicians said in public
HCP commentary reports on 8 clinical trials sponsored by Roche, including CUPISCO, IMpassion050, Krascendo 1 and SKYSCRAPER-03. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 87 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Hoffmann-La Roche; Genentech, Inc.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| MORPHEUS-panBC NCT03424005 · Hoffmann-La Roche | metastatic breast cancer | Phase 1/Phase 2 | 7 | 4 | Focused | Nov 20, 2026 | Preview |
| CEVOLUTION NCT07555938 · Hoffmann-La Roche | previously treated multiple myeloma | Phase 3 | 8 | 1 | Focused | Nov 9, 2026 | Preview |
| Krascendo 1 NCT06497556 · Hoffmann-La Roche | previously treated KRAS G12C-positive non-small cell lung cancer | Phase 3 | 481 | 181 | Deep | Nov 5, 2026 | Preview |
| KRASCENDO 3 NCT07541170 · Hoffmann-La Roche | resected stage II-III KRAS G12C-positive NSCLC | Phase 3 | 10 | 6 | Focused | Nov 1, 2026 | Preview |
| AcceleRET-Lung NCT04222972 · Hoffmann-La Roche | first-line RET fusion-positive metastatic non-small cell lung cancer | Phase 3 | 63 | 26 | Focused | Nov 1, 2026 | Preview |
| CUPISCO NCT03498521 · Hoffmann-La Roche | unfavourable cancer of unknown primary | Phase 2 | 358 | 62 | Deep | Oct 31, 2026 | Preview |
| IMpassion050 NCT03726879 · Hoffmann-La Roche | HER2-positive early breast cancer | Phase 3 | 175 | 16 | Standard | Oct 31, 2026 | Preview |
| SKYSCRAPER-03 NCT04513925 · Hoffmann-La Roche | locally advanced, unresectable stage III NSCLC | Phase 3 | 122 | 39 | Focused | Oct 31, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| POLARIX NCT03274492 · Hoffmann-La Roche DeepView → | previously untreated diffuse large B-cell lymphoma | Phase 3 | Deep | View | |||
| IMpower133 NCT02763579 · Hoffmann-La Roche DeepView → | untreated extensive-stage small cell lung cancer | Phase 3 | Deep | View | |||
| IMpower150 NCT02366143 · Hoffmann-La Roche DeepView → | first-line metastatic nonsquamous non-small cell lung cancer | Phase 3 | Deep | View | |||
| IMbrave150 NCT03434379 · Hoffmann-La Roche DeepView → | untreated locally advanced or metastatic hepatocellular carcinoma | Phase 3 | Deep | View | |||
| IMforte NCT05091567 · Hoffmann-La Roche DeepView → | extensive-stage small-cell lung cancer | Phase 3 | Deep | View | |||
| IMvigor010 NCT02450331 · Hoffmann-La Roche DeepView → | high-risk muscle-invasive urothelial carcinoma after surgical resection | Phase 3 | Deep | View | |||
| IMvigor130 NCT02807636 · Hoffmann-La Roche DeepView → | untreated locally advanced or metastatic urothelial carcinoma | Phase 3 | Deep | View | |||
| evERA NCT05306340 · Genentech, Inc. DeepView → | ER-positive, HER2-negative locally advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| ALEX NCT02075840 · Hoffmann-La Roche DeepView → | treatment-naive advanced ALK-positive non-small-cell lung cancer | Phase 3 | Deep | View | |||
| MURANO NCT02005471 · Hoffmann-La Roche DeepView → | relapsed/refractory chronic lymphocytic leukemia | Phase 3 | Deep | View | |||
| STARGLO NCT04408638 · Hoffmann-La Roche DeepView → | relapsed/refractory diffuse large B-cell lymphoma | Phase 3 | Deep | View | |||
| IMmotion010 NCT03024996 · Hoffmann-La Roche DeepView → | high-risk renal cell carcinoma following nephrectomy | Phase 3 | Deep | View | |||
| INAVO120 NCT04191499 · Hoffmann-La Roche DeepView → | PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer | Phase 2/Phase 3 | Deep | View | |||
| APHINITY NCT01358877 · Hoffmann-La Roche DeepView → | HER2-positive early breast cancer | Phase 3 | Deep | View | |||
| IMmotion151 NCT02420821 · Hoffmann-La Roche DeepView → | previously untreated metastatic renal cell carcinoma | Phase 3 | Deep | View | |||
| IMpassion130 NCT02425891 · Hoffmann-La Roche DeepView → | previously untreated metastatic triple-negative breast cancer | Phase 3 | Deep | View | |||
| SKYSCRAPER-02 NCT04256421 · Hoffmann-La Roche DeepView → | untreated extensive-stage small cell lung cancer | Phase 3 | Deep | View | |||
| persevERA NCT04546009 · Hoffmann-La Roche DeepView → | Not given | Phase 3 | Deep | View | |||
| SUNMO NCT05171647 · Hoffmann-La Roche DeepView → | transplant-ineligible relapsed/refractory large B-cell lymphoma | Phase 3 | Deep | View | |||
| IMpower130 NCT02367781 · Hoffmann-La Roche DeepView → | stage IV non-squamous non-small cell lung cancer | Phase 3 | Deep | View | |||
| GALLIUM NCT01332968 · Hoffmann-La Roche DeepView → | previously untreated advanced indolent non-Hodgkin lymphoma | Phase 3 | Deep | View | |||
| POLARGO NCT04182204 · Hoffmann-La Roche DeepView → | relapsed/refractory diffuse large B-cell lymphoma | Phase 3 | Deep | View | |||
| IMpassion031 NCT03197935 · Hoffmann-La Roche DeepView → | early-stage triple-negative breast cancer | Phase 3 | Deep | View | |||
| OAK NCT02008227 · Hoffmann-La Roche DeepView → | advanced non-small cell lung cancer after platinum-containing therapy | Phase 3 | Deep | View | |||
| IMpower010 NCT02486718 · Hoffmann-La Roche DeepView → | resected stage IB-IIIA non-small cell lung cancer | Phase 3 | Deep | View | |||
| NAUTIKA1 NCT04302025 · Genentech, Inc. DeepView → | biomarker-selected resectable stages IB-III NSCLC | Phase 2 | Deep | View | |||
| IMpassion030 NCT03498716 · Hoffmann-La Roche DeepView → | operable triple-negative breast cancer | Phase 3 | Deep | View | |||
| MyPathway NCT02091141 · Genentech, Inc. DeepView → | advanced solid tumors with molecular alterations | Phase 2 | Deep | View | |||
| IMvigor211 NCT02302807 · Hoffmann-La Roche DeepView → | platinum-treated locally advanced or metastatic urothelial carcinoma | Phase 3 | Deep | View | |||
| SKYSCRAPER-01 NCT04294810 · Hoffmann-La Roche DeepView → | Not given | Phase 3 | Deep | View | |||
| IMbrave251 NCT04770896 · Hoffmann-La Roche DeepView → | hepatocellular carcinoma previously treated with atezolizumab and bevacizumab | Phase 3 | Deep | View | |||
| IPATential150 NCT03072238 · Hoffmann-La Roche DeepView → | previously untreated metastatic castration-resistant prostate cancer | Phase 3 | Deep | View | |||
| IPSOS NCT03191786 · Hoffmann-La Roche DeepView → | platinum-ineligible advanced non-small cell lung cancer | Phase 3 | Deep | View | |||
| CITYSCAPE NCT03563716 · Genentech, Inc. DeepView → | first-line PD-L1-selected non-small-cell lung cancer | Phase 2 | Deep | View | |||
| IMpassion131 NCT03125902 · Hoffmann-La Roche DeepView → | first-line unresectable locally advanced/metastatic triple-negative breast cancer | Phase 3 | Deep | View | |||
| AURELIA NCT00976911 · Hoffmann-La Roche DeepView → | platinum-resistant recurrent ovarian cancer | Phase 3 | Deep | View | |||
| MorningSun NCT05207670 · Genentech, Inc. DeepView → | non-Hodgkin lymphoma | Phase 2 | Deep | View | |||
| Krascendo-170 NCT05789082 · Hoffmann-La Roche DeepView → | untreated KRAS G12C+ advanced non-small cell lung cancer | Phase 1/Phase 2 | Deep | View | |||
| STARTRK-1 NCT02097810 · Hoffmann-La Roche DeepView → | NTRK/ROS1/ALK-positive advanced or metastatic solid tumors | Phase 1 | Deep | View | |||
| GOYA NCT01287741 · Hoffmann-La Roche DeepView → | previously untreated CD20-positive diffuse large B-cell lymphoma | Phase 3 | Deep | View | |||
| STARTRK-2 NCT02568267 · Hoffmann-La Roche DeepView → | Not given | Phase 2 | Deep | View | |||
| CELESTIMO NCT04712097 · Hoffmann-La Roche DeepView → | relapsed or refractory follicular lymphoma | Phase 3 | Deep | View | |||
| TALENTACE NCT04712643 · Hoffmann-La Roche DeepView → | untreated hepatocellular carcinoma | Phase 3 | Deep | View | |||
| CONTACT-01 NCT04471428 · Hoffmann-La Roche DeepView → | previously treated metastatic non-small cell lung cancer | Phase 3 | Deep | View | |||
| IMpower132 NCT02657434 · Hoffmann-La Roche DeepView → | stage IV non-squamous non-small cell lung cancer | Phase 3 | Deep | View | |||
| IMbrave151 NCT04677504 · Hoffmann-La Roche DeepView → | untreated advanced biliary tract cancer | Phase 2 | Deep | View | |||
| CLL11 NCT01010061 · Hoffmann-La Roche DeepView → | previously untreated chronic lymphocytic leukemia with comorbidities | Phase 3 | Deep | View | |||
| BFAST NCT03178552 · Hoffmann-La Roche DeepView → | advanced or metastatic non-small cell lung cancer | Phase 2/Phase 3 | Deep | View | |||
| IMvigor011 NCT04660344 · Hoffmann-La Roche DeepView → | ctDNA-positive high-risk muscle-invasive bladder cancer following cystectomy | Phase 3 | Deep | View | |||
| NP30179 NCT03075696 · Hoffmann-La Roche DeepView → | relapsed/refractory B-cell non-Hodgkin lymphoma | Phase 1/Phase 2 | Deep | View | |||
| GO29365 NCT02257567 · Hoffmann-La Roche StandardView → | relapsed/refractory follicular or diffuse large B-cell lymphoma | Phase 1/Phase 2 | Standard | View | |||
| LCMC3 NCT02927301 · Genentech, Inc. StandardView → | resectable non-small cell lung cancer | Phase 2 | Standard | View | |||
| ALESIA NCT02838420 · Hoffmann-La Roche StandardView → | treatment-naive ALK-positive advanced non-small cell lung cancer | Phase 3 | Standard | View | |||
| IMpower151 NCT04194203 · Hoffmann-La Roche StandardView → | chemotherapy-naïve stage IV non-squamous non-small cell lung cancer | Phase 3 | Standard | View | |||
| ASTEFANIA NCT04873362 · Hoffmann-La Roche StandardView → | high-risk HER2-positive breast cancer following preoperative therapy | Phase 3 | Standard | View | |||
| INAVO123 NCT06790693 · Hoffmann-La Roche StandardView → | endocrine-sensitive PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer | Phase 3 | Standard | View | |||
| Krascendo 2 NCT06793215 · Hoffmann-La Roche StandardView → | Not given | Phase 3 | Standard | View | |||
| IMbrave050 NCT04102098 · Hoffmann-La Roche StandardView → | high-risk hepatocellular carcinoma after resection or ablation | Phase 3 | Standard | View | |||
| IMbassador250 NCT03016312 · Hoffmann-La Roche StandardView → | metastatic castration-resistant prostate cancer | Phase 3 | Standard | View | |||
| MORPHEUS-UC NCT03869190 · Hoffmann-La Roche StandardView → | urothelial carcinoma | Phase 1/Phase 2 | Standard | View | |||
| IMblaze370 NCT02788279 · Hoffmann-La Roche StandardView → | previously treated metastatic colorectal cancer | Phase 3 | Standard | View | |||
| ALINA NCT03456076 · Hoffmann-La Roche StandardView → | resected stage IB–IIIA ALK-positive non-small cell lung cancer | Phase 3 | Standard | View | |||
| FeDeriCa NCT03493854 · Hoffmann-La Roche StandardView → | HER2-positive early breast cancer | Phase 3 | Standard | View | |||
| HORIZON 1 NCT05170204 · Hoffmann-La Roche StandardView → | unresectable stage III non-small cell lung cancer | Phase 3 | Standard | View | |||
| SKYSCRAPER-05 NCT04832854 · Hoffmann-La Roche FocusedView → | previously untreated locally advanced resectable stage II–IIIB NSCLC | Phase 2 | Focused | View | |||
| IMCODE001 NCT03815058 · Genentech, Inc. FocusedView → | previously untreated advanced melanoma | Phase 2 | Focused | View | |||
| CONTACT-03 NCT04338269 · Hoffmann-La Roche FocusedView → | renal cell carcinoma after immune checkpoint inhibitor treatment | Phase 3 | Focused | View | |||
| MIRROS NCT02545283 · Hoffmann-La Roche FocusedView → | relapsed or refractory acute myeloid leukemia | Phase 3 | Focused | View | |||
| ARROW NCT03037385 · Hoffmann-La Roche FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| IMCODE003 NCT05968326 · Genentech, Inc. FocusedView → | resected pancreatic ductal adenocarcinoma | Phase 2 | Focused | View | |||
| CAVALLI NCT02055820 · Hoffmann-La Roche FocusedView → | B-cell non-Hodgkin lymphoma | Phase 1/Phase 2 | Focused | View | |||
| NCT02500407 NCT02500407 · Genentech, Inc. FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| NCT03671018 NCT03671018 · Hoffmann-La Roche FocusedView → | relapsed or refractory B-cell non-Hodgkin lymphoma | Phase 1/Phase 2 | Focused | View | |||
| ROMULUS NCT01691898 · Genentech, Inc. FocusedView → | relapsed or refractory B-cell non-Hodgkin lymphoma | Phase 1/Phase 2 | Focused | View | |||
| NCT03677141 NCT03677141 · Hoffmann-La Roche FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| IMscin001 NCT03735121 · Hoffmann-La Roche FocusedView → | previously treated locally advanced or metastatic NSCLC | Phase 3 | Focused | View | |||
| NP28673 NCT01801111 · Hoffmann-La Roche FocusedView → | crizotinib-resistant ALK-positive non-small cell lung cancer | Phase 1/Phase 2 | Focused | View | |||
| NP28761 NCT01871805 · Hoffmann-La Roche FocusedView → | ALK-positive crizotinib-resistant non-small cell lung cancer | Phase 1/Phase 2 | Focused | View | |||
| NCT02013219 NCT02013219 · Hoffmann-La Roche FocusedView → | advanced non-small cell lung cancer | Phase 1 | Focused | View | |||
| IPATunity130 NCT03337724 · Hoffmann-La Roche FocusedView → | PIK3CA/AKT1/PTEN-altered advanced HER2-negative breast cancer | Phase 3 | Focused | View | |||
| SKYSCRAPER-02C NCT04665856 · Hoffmann-La Roche FocusedView → | untreated extensive-stage small cell lung cancer | Phase 3 | Focused | View | |||
| STARTRK-NG NCT02650401 · Hoffmann-La Roche FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| NCT03275103 NCT03275103 · Genentech, Inc. FocusedView → | Not given | Phase 1 | Focused | View | |||
| NCT03289962 NCT03289962 · Genentech, Inc. FocusedView → | Not given | Phase 1 | Focused | View | |||
| ML41253 NCT04321330 · Hoffmann-La Roche FocusedView → | previously-treated advanced thymic carcinoma | Phase 2 | Focused | View | |||
| NCT04557150 NCT04557150 · Hoffmann-La Roche FocusedView → | relapsed or refractory multiple myeloma | Phase 1 | Focused | View | |||
| IMscin002 NCT05171777 · Hoffmann-La Roche FocusedView → | non-small cell lung cancer | Phase 2 | Focused | View | |||